eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.imagine a congressional hearing held before media cameras, with reporters all over the us and europe ready with shocking articles about one of the leading causes of death�
.
.